Companies will combine technologies to generate fully human MASP-2 antibodies
Omeros and Affitech entered an agreement to develop fully human antibodies for Omeros’ MASP-2 program. Financial terms include a technology access fee, a series of milestone payments, and royalties on net sales payable by Omeros.
Omeros holds worldwide exclusive licenses to rights related to MASP-2, the antibodies targeting MASP-2, and the therapeutic applications for those antibodies. Affitech will use its human antibody libraries and AffiScreen™ platform to generate fully human MASP-2 antibodies for Omeros.
MASP-2, or mannan-binding lectin-associated serine protease-2, mediates activation of the complement system via the lectin pathway. It is linked to multiple potential inflammatory diseases including macular degeneration, rheumatoid arthritis, transplant rejection, and cardiovascular and renal ischemia-reperfusion injury, according to the firms.
